Aldeyra plots third FDA filing for dry eye disease drug after latest Phase 3 data
Aldeyra Therapeutics isn’t giving up on its drug candidate for dry eye disease despite a challenging path so far.
The company is preparing to file …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
